PTHS insider transaction filings
Pelthos Therapeutics Inc. — 38 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-07. Screen PTHS transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-07 | 4 | Friedberg Ezra M — Director | Sale (S): 534 @ $26.03 · Sale (S): 24 @ $27.33 | EDGAR |
| 2026-07-07 | 4 | Pauls Matthew — Director | Sale (S): 692 @ $26.00 · Sale (S): 94 @ $27.36 | EDGAR |
| 2026-07-07 | 4 | Greenleaf Peter — Director | Sale (S): 712 @ $26.00 · Sale (S): 85 @ $27.27 | EDGAR |
| 2026-06-17 | 4 | Friedberg Ezra M — Director | Sale (S): 224 @ $27.12 · Sale (S): 59 @ $27.94 | EDGAR |
| 2026-06-15 | 4 | Davis Todd C — Director | Purchase (P): 35,445 @ $27.80 · Purchase (P): 503 @ $28.73 | EDGAR |
| 2026-05-26 | 4 | Francis Knuettel II — CFO, Treas & Secty | Disposition to issuer (D): 13,947 @ $0 · Sale (S): 1,500 @ $26.84 · Grant/award (A): 59,500 (derivative) · Disposition to issuer (D): 42,500 (derivative) | EDGAR |
| 2026-05-18 | 4 | Friedberg Ezra M — Director | Tax withholding (F): 144 @ $27.01 | EDGAR |
| 2026-04-06 | 4 | Malamut Richard — Director | Sale (S): 310 @ $20.51 · Sale (S): 280 @ $21.36 | EDGAR |
| 2026-04-06 | 4 | Friedberg Ezra M — Director | Sale (S): 293 @ $20.51 · Sale (S): 265 @ $21.36 | EDGAR |
| 2026-04-06 | 4 | Pauls Matthew — Director | Sale (S): 415 @ $20.52 · Sale (S): 371 @ $21.36 | EDGAR |
| 2026-04-06 | 4 | Greenleaf Peter — Director | Sale (S): 420 @ $20.52 · Sale (S): 377 @ $21.36 | EDGAR |
| 2026-04-01 | 4/A | Rangarao Sai — Chief Commercial Officer | Grant/award (A): 30,518 @ $0 | EDGAR |
| 2026-04-01 | 4/A | Baxter Richard B — Director | Grant/award (A): 19,108 @ $0 | EDGAR |
| 2026-04-01 | 4/A | Malamut Richard — Director | Grant/award (A): 6,450 @ $0 · Grant/award (A): 2,454 @ $0 · Grant/award (A): 19,108 @ $0 | EDGAR |
| 2026-04-01 | 4/A | Plesha Scott M. — CEO and President, Director | Grant/award (A): 83,678 @ $0 | EDGAR |
| 2026-04-01 | 4/A | Friedberg Ezra M — Director | Grant/award (A): 6,450 @ $0 · Grant/award (A): 2,454 @ $0 · Grant/award (A): 19,108 @ $0 | EDGAR |
| 2026-04-01 | 4/A | Pauls Matthew — Director | Grant/award (A): 25,478 @ $0 | EDGAR |
| 2026-04-01 | 4/A | Francis Knuettel II — CFO, Treas & Secty | Grant/award (A): 33,472 @ $0 | EDGAR |
| 2026-04-01 | 4/A | Davis Todd C — Director | Grant/award (A): 12,900 @ $0 · Grant/award (A): 4,961 @ $0 · Grant/award (A): 19,108 @ $0 | EDGAR |
| 2026-04-01 | 4/A | Greenleaf Peter — Director | Grant/award (A): 25,478 @ $0 | EDGAR |
| 2025-12-29 | 4 | Einhorn Andrew J. — Director | Grant/award (A): 12,000 | EDGAR |
| 2025-12-19 | 4 | LIGAND PHARMACEUTICALS INC — Director, 10% owner | Disposition to issuer (D) · Grant/award (A) | EDGAR |
| 2025-12-12 | 4 | Pauls Matthew — Director | Option exercise (M): 8,493 @ $0 · Option exercise (M): 2,123 @ $0 · Gift (G): 9,542 @ $0 · Option exercise (M): 8,493 (derivative) @ $0 · Option exercise (M): 2,123 (derivative) @ $0 | EDGAR |
| 2025-11-26 | 4 | Friedberg Ezra M — Director | Sale (S): 5,999 @ $28 · Sale (S): 2,000 @ $28.14 · Sale (S): 1 @ $28.50 · Sale (S): 2,000 @ $28.00 | EDGAR |
| 2025-11-10 | 4 | LIGAND PHARMACEUTICALS INC — Director, 10% owner | Grant/award (A) @ $9,000,000 | EDGAR |
| 2025-07-23 | 4 | Plesha Scott M. — CEO and President, Director | Grant/award (A): 83,678 (derivative) · Grant/award (A): 255,000 (derivative) | EDGAR |
| 2025-07-21 | 4 | Rangarao Sai — Chief Commercial Officer | Grant/award (A): 30,518 (derivative) · Grant/award (A): 93,000 (derivative) | EDGAR |
| 2025-07-07 | 4 | Baxter Richard B — Director | Grant/award (A): 19,108 (derivative) · Grant/award (A): 58,230 (derivative) | EDGAR |
| 2025-07-07 | 4 | Malamut Richard — Director | Grant/award (A): 19,108 (derivative) · Grant/award (A): 58,230 (derivative) | EDGAR |
| 2025-07-07 | 4 | Friedberg Ezra M — Director | Grant/award (A): 19,108 (derivative) · Grant/award (A): 58,230 (derivative) | EDGAR |
| 2025-07-07 | 4 | Pauls Matthew — Director | Grant/award (A): 25,478 (derivative) · Grant/award (A): 77,640 (derivative) | EDGAR |
| 2025-07-07 | 4 | Francis Knuettel II — CFO, Treas & Secty | Grant/award (A): 33,472 (derivative) · Grant/award (A): 102,000 (derivative) | EDGAR |
| 2025-07-07 | 4 | Davis Todd C — Director | Grant/award (A): 19,108 (derivative) · Grant/award (A): 58,230 (derivative) | EDGAR |
| 2025-07-07 | 4 | Greenleaf Peter — Director | Grant/award (A): 25,478 (derivative) · Grant/award (A): 77,640 (derivative) | EDGAR |
| 2025-07-03 | 4 | LIGAND PHARMACEUTICALS INC — 10% owner | Conversion (C): 1,500,000 @ $10 · Conversion (C): 15,000 (derivative) @ $0 · Other (J): 31,278.68 (derivative) | EDGAR |
| 2025-07-03 | 4 | Friedberg Ezra M — Director | Conversion (C): 40,000 @ $10 · Conversion (C): 40,000 @ $10 · Purchase (P): 40,000 (derivative) @ $0 · Purchase (P): 40,000 (derivative) @ $0 · Conversion (C): 40,000 (derivative) @ $0 · Conversion (C): 40,000 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | Francis Knuettel II — Chief Financial Officer | Conversion (C): 10,000 @ $10 · Other (J): 10,000 (derivative) @ $0 · Conversion (C): 10,000 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | Davis Todd C — Director, 10% owner | Conversion (C): 1,500,000 @ $10 · Conversion (C): 15,000 (derivative) @ $0 · Other (J): 31,278.68 (derivative) | EDGAR |
Recent 8-K events — Pelthos Therapeutics Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-13 | 8-K | 4.02 — Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review | EDGAR |
| 2026-05-28 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-21 | 8-K | 4.01 — Changes in Registrant's Certifying Accountant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-14 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-10 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-19 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=PTHS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →